Botulinum toxin type B (BoNT-B), known as Myobloc® in the United States and as Neurobloc® in Europe, is a new therapeutically available serotype among the botulinum toxin family. During the last years several data have been reported in literature investigating its efficacy and safety, as well as defining the dosing and application regiments of BoNT-B in the treatment of hyperhidrosis. Moreover, recent studies have been examining its safety profile, which may be different from those known about BoNT-A. The aim of this review is to provide information about what is currently known about BoNT-B in regards to the treatment of focal hyperhidrosis.
Keywords: axillary hyperhidrosis; botulinum toxin type B; compensatory hyperhidrosis; craniofacial hyperhidrosis; focal hyperhidrosis; palmar hyperhidrosis; plantar hyperhidrosis; residual hyperhidrosis.